Compare Stocks: LAB, CYRX, MLAB, and OABI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYRX CryoPort	$16.09 -2.9%	$15.67	$7.61 ▼ $17.20	$814.94M	1.89	559,362 shs	431,151 shs
LAB Standard BioTools	$0.64 -1.7%	$0.80	$0.63 ▼ $1.72	$252M	1.4	1.43 million shs	1.26 million shs
MLAB Mesa Laboratories	$129.09 +0.3%	$104.42	$58.83 ▼ $129.66	$722.37M	0.92	166,849 shs	153,074 shs
OABI OmniAb	$4.47 -3.0%	$2.77	$1.30 ▼ $4.93	$647.18M	0.45	2.23 million shs	1.30 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYRX CryoPort	0.00%	-6.07%	+4.96%	+2.55%	+83.47%
LAB Standard BioTools	0.00%	-4.05%	-28.46%	-44.18%	-49.85%
MLAB Mesa Laboratories	0.00%	+3.47%	+27.76%	+26.53%	+87.66%
OABI OmniAb	0.00%	+3.23%	+124.62%	+65.56%	+177.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYRX CryoPort	$16.09 -2.9%	$15.67	$7.61 ▼ $17.20	$814.94M	1.89	559,362 shs	431,151 shs
LAB Standard BioTools	$0.64 -1.7%	$0.80	$0.63 ▼ $1.72	$252M	1.4	1.43 million shs	1.26 million shs
MLAB Mesa Laboratories	$129.09 +0.3%	$104.42	$58.83 ▼ $129.66	$722.37M	0.92	166,849 shs	153,074 shs
OABI OmniAb	$4.47 -3.0%	$2.77	$1.30 ▼ $4.93	$647.18M	0.45	2.23 million shs	1.30 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYRX CryoPort	0.00%	-6.07%	+4.96%	+2.55%	+83.47%
LAB Standard BioTools	0.00%	-4.05%	-28.46%	-44.18%	-49.85%
MLAB Mesa Laboratories	0.00%	+3.47%	+27.76%	+26.53%	+87.66%
OABI OmniAb	0.00%	+3.23%	+124.62%	+65.56%	+177.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYRX CryoPort	2.67	Moderate Buy	$18.00	11.87% Upside
LAB Standard BioTools	1.67	Reduce	$1.35	110.31% Upside
MLAB Mesa Laboratories	2.00	Hold	$110.00	-14.79% Downside
OABI OmniAb	2.33	Hold	$11.00	146.09% Upside

Current Analyst Ratings Breakdown

Latest LAB, CYRX, MLAB, and OABI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	OABI OmniAb	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	CYRX CryoPort	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/17/2026	OABI OmniAb	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/14/2026	MLAB Mesa Laboratories	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$94.00 ➝ $110.00
8/11/2026	MLAB Mesa Laboratories	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
8/7/2026	LAB Standard BioTools	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/7/2026	CYRX CryoPort	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$12.00 ➝ $16.00
8/7/2026	CYRX CryoPort	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$21.00
8/7/2026	CYRX CryoPort	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$15.00 ➝ $19.00
8/6/2026	OABI OmniAb	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	CYRX CryoPort	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYRX CryoPort	$176.18M	4.63	N/A	N/A	$8.77 per share	1.83
LAB Standard BioTools	$85.33M	2.95	N/A	N/A	$1.38 per share	0.47
MLAB Mesa Laboratories	$249.13M	2.90	$11.78 per share	10.96	$33.73 per share	3.83
OABI OmniAb	$18.67M	34.66	N/A	N/A	$1.80 per share	2.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYRX CryoPort	$78.30M	-$0.90	N/A	N/A	N/A	-20.05%	-7.20%	-4.30%	11/3/2026 (Estimated)
LAB Standard BioTools	-$74.90M	$0.22	2.92	N/A	N/A	100.36%	-7.57%	-6.14%	11/3/2026 (Estimated)
MLAB Mesa Laboratories	$6.71M	$0.84	153.68	N/A	N/A	1.92%	22.72%	9.82%	11/5/2026 (Estimated)
OABI OmniAb	-$64.78M	-$0.36	N/A	N/A	N/A	-115.12%	-16.59%	-14.82%	11/3/2026 (Estimated)

Latest LAB, CYRX, MLAB, and OABI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q1 2027	MLAB Mesa Laboratories	N/A	$2.68	N/A	$0.49	N/A	$60.14 million
8/6/2026	Q2 2026	CYRX CryoPort	-$0.1933	-$0.20	-$0.0067	-$0.20	$48.18 million	$48.97 million
8/6/2026	Q2 2026	OABI OmniAb	-$0.12	-$0.05	+$0.07	-$0.05	$4.69 million	$13.42 million
8/5/2026	Q2 2026	LAB Standard BioTools	-$0.0128	-$0.07	-$0.0573	-$0.07	$20.80 million	$20.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
LAB Standard BioTools	N/A	N/A	N/A	N/A	N/A
MLAB Mesa Laboratories	$0.64	0.50%	N/A	76.19%	N/A
OABI OmniAb	N/A	N/A	N/A	N/A	N/A

Latest LAB, CYRX, MLAB, and OABI Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/6/2026	MLAB Mesa Laboratories	quarterly	$0.16	0.62%	8/31/2026	8/31/2026	9/15/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYRX CryoPort	N/A	2.08	1.98
LAB Standard BioTools	N/A	9.10	8.80
MLAB Mesa Laboratories	0.73	1.79	1.32
OABI OmniAb	N/A	4.80	4.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYRX CryoPort	92.90%
LAB Standard BioTools	53.74%
MLAB Mesa Laboratories	90.60%
OABI OmniAb	72.08%

Insider Ownership

Company	Insider Ownership
CYRX CryoPort	9.50%
LAB Standard BioTools	26.81%
MLAB Mesa Laboratories	2.80%
OABI OmniAb	9.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYRX CryoPort	1,186	50.65 million	45.84 million	Optionable
LAB Standard BioTools	620	392.58 million	287.33 million	Optionable
MLAB Mesa Laboratories	680	5.60 million	5.44 million	Not Optionable
OABI OmniAb	7	144.78 million	130.59 million	Optionable

LAB, CYRX, MLAB, and OABI Headlines

Recent News About These Companies

Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI?

August 28 at 5:30 PM | finance.yahoo.com

OmniAb, Inc. (OABI) Latest Press Releases & Corporate News - Yahoo Finance

August 28 at 12:24 PM | finance.yahoo.com

OmniAb (NASDAQ:OABI) Trading Down 5.1% - Here's Why

August 27 at 12:59 PM | marketbeat.com

OmniAb (NASDAQ:OABI) Shares Up 5.8% - What's Next?

August 26, 2026 | marketbeat.com

Whitefort Capital Management LP Takes $25.21 Billion Position in OmniAb, Inc. $OABI

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in OmniAb, Inc. $OABI

August 26, 2026 | marketbeat.com

OmniAb (NASDAQ:OABI) Sets New 12-Month High - Still a Buy?

August 24, 2026 | marketbeat.com

OmniAb Earnings Call Highlights Surging Growth, Clinical Wins

August 20, 2026 | theglobeandmail.com

OmniAb (NASDAQ:OABI) Trading 5.3% Higher - What's Next?

August 20, 2026 | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for OmniAb (NASDAQ:OABI)

August 19, 2026 | americanbankingnews.com

OmniAb Inc (OABI) Stock Price, Quote, News & History

August 18, 2026 | benzinga.com

OmniAb (NASDAQ:OABI) Sees Unusually-High Trading Volume - Here's Why

August 18, 2026 | marketbeat.com

OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech

August 18, 2026 | seekingalpha.com

Rice Hall James & Associates LLC Acquires New Stake in OmniAb, Inc. $OABI

August 18, 2026 | marketbeat.com

OmniAb Enters Global Collaboration With Eli Lilly for Ion Channel Program; Raises Full-Year Cash Outlook

August 17, 2026 | finance.yahoo.com

HC Wainwright Reiterates Buy Rating for OmniAb (NASDAQ:OABI)

August 17, 2026 | marketbeat.com

OmniAb (NASDAQ:OABI) Reaches New 1-Year High - What's Next?

August 17, 2026 | marketbeat.com

OmniAb lifts 2026 cash outlook following licensing momentum

August 17, 2026 | msn.com

OmniAb Raises 2026 Financial Guidance

August 17, 2026 | businesswire.com

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

August 17, 2026 | businesswire.com

Dimensional Fund Advisors LP Has $2.74 Million Stake in OmniAb, Inc. $OABI

August 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LAB, CYRX, MLAB, and OABI Company Descriptions

CryoPort NASDAQ:CYRX

$16.09 -0.48 (-2.90%)

As of 08/28/2026 04:00 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Standard BioTools NASDAQ:LAB

$0.64 -0.01 (-1.70%)

As of 08/28/2026 04:00 PM Eastern

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Mesa Laboratories NASDAQ:MLAB

$129.09 +0.44 (+0.34%)

As of 08/28/2026 04:00 PM Eastern

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

OmniAb NASDAQ:OABI

$4.47 -0.14 (-3.04%)

As of 08/28/2026 04:00 PM Eastern

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LAB, CYRX, MLAB, and OABI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LAB, CYRX, MLAB, and OABI Earnings

Compare Dividends

Latest LAB, CYRX, MLAB, and OABI Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LAB, CYRX, MLAB, and OABI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LAB, CYRX, MLAB, and OABI Company Descriptions

CryoPort NASDAQ:CYRX

Standard BioTools NASDAQ:LAB

Mesa Laboratories NASDAQ:MLAB

OmniAb NASDAQ:OABI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools